PMID- 33901051 OWN - NLM STAT- MEDLINE DCOM- 20210924 LR - 20230825 IS - 2163-0763 (Electronic) IS - 2163-0755 (Linking) VI - 91 IP - 3 DP - 2021 Sep 1 TI - A tale of two centers: Is low-molecular-weight heparin really superior for prevention of posttraumatic venous thromboembolism? PG - 537-541 LID - 10.1097/TA.0000000000003257 [doi] AB - BACKGROUND: Low-molecular-weight heparin (LMWH) is widely used for venous thromboembolism chemoprophylaxis following injury. However, unfractionated heparin (UFH) is a less expensive option. We compared LMWH and UFH for prevention of posttraumatic deep venous thrombosis (DVT) and pulmonary embolism (PE). METHODS: Trauma patients 15 years or older with at least one administration of venous thromboembolism chemoprophylaxis at two level I trauma centers with similar DVT-screening protocols were identified. Center 1 administered UFH every 8 hours for chemoprophylaxis, and center 2 used twice-daily antifactor Xa-adjusted LMWH. Clinical characteristics and primary chemoprophylaxis agent were evaluated in a two-level logistic regression model. Primary outcome was incidence of DVT and PE. RESULTS: There were 3,654 patients: 1,155 at center 1 and 2,499 at center 2. The unadjusted DVT rate at center 1 was lower than at center 2 (3.5% vs. 5.0%; p = 0.04); PE rates did not significantly differ (0.4% vs. 0.6%; p = 0.64). Patients at center 2 were older (mean, 50.3 vs. 47.3 years; p < 0.001) and had higher Injury Severity Scores (median, 10 vs. 9; p < 0.001), longer stays in the hospital (mean, 9.4 vs. 7.0 days; p < 0.001) and intensive care unit (mean, 3.0 vs. 1.3 days; p < 0.001), and a higher mortality rate (1.6% vs. 0.6%, p = 0.02) than patients at center 1. Center 1's patients received their first dose of chemoprophylaxis earlier than patients at center 2 (median, 1.0 vs. 1.7 days; p < 0.001). After risk adjustment and accounting for center effects, primary chemoprophylaxis agent was not associated with risk of DVT (odds ratio, 1.01; 95% confidence interval, 0.69-1.48; p = 0.949). Cost calculations showed that UFH was less expensive than LMWH. CONCLUSION: Primary utilization of UFH is not inferior to LMWH for posttraumatic DVT chemoprophylaxis and rates of PE are similar. Given that UFH is lower in cost, the choice of this chemoprophylaxis agent may have major economic implications. LEVEL OF EVIDENCE: Prognostic and epidemiological, level II; Therapeutic, level III. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Checchi, Kyle D AU - Checchi KD AD - From the Trauma Service, Department of Surgery (K.D.C., J.B., R.Y.C., A.S.R., L.E.W., J.M.P., C.B.S., M.J.S., M.J.M., V.B.), Scripps Mercy Hospital; Division of Trauma, Surgical Critical Care, Burns and Acute Care Surgery, Department of Surgery (T.W.C., A.E.B.), University of California San Diego, San Diego, California. FAU - Costantini, Todd W AU - Costantini TW FAU - Badiee, Jayraan AU - Badiee J FAU - Berndtson, Allison E AU - Berndtson AE FAU - Calvo, Richard Y AU - Calvo RY FAU - Rooney, Alexandra S AU - Rooney AS FAU - Wessels, Lyndsey E AU - Wessels LE FAU - Prieto, James M AU - Prieto JM FAU - Sise, C Beth AU - Sise CB FAU - Sise, Michael J AU - Sise MJ FAU - Martin, Matthew J AU - Martin MJ FAU - Bansal, Vishal AU - Bansal V LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study PL - United States TA - J Trauma Acute Care Surg JT - The journal of trauma and acute care surgery JID - 101570622 RN - 0 (Anticoagulants) RN - 0 (Heparin, Low-Molecular-Weight) RN - 9005-49-6 (Heparin) SB - IM MH - Adult MH - Aged MH - Anticoagulants/economics/*therapeutic use MH - California/epidemiology MH - Female MH - Heparin/economics/*therapeutic use MH - Heparin, Low-Molecular-Weight/economics/therapeutic use MH - Humans MH - Injury Severity Score MH - Logistic Models MH - Male MH - Middle Aged MH - Pulmonary Embolism/epidemiology/*prevention & control MH - Trauma Centers MH - Venous Thromboembolism/epidemiology/etiology/*prevention & control MH - Wounds and Injuries/*complications EDAT- 2021/04/27 06:00 MHDA- 2021/09/25 06:00 CRDT- 2021/04/26 17:18 PHST- 2021/04/27 06:00 [pubmed] PHST- 2021/09/25 06:00 [medline] PHST- 2021/04/26 17:18 [entrez] AID - 01586154-202109000-00013 [pii] AID - 10.1097/TA.0000000000003257 [doi] PST - ppublish SO - J Trauma Acute Care Surg. 2021 Sep 1;91(3):537-541. doi: 10.1097/TA.0000000000003257.